 |
 |
|
Home |
Current Issue |
Past Issues |
In the Clinic |
ACP Journal Club |
CME |
Collections |
Audio/Video |
Mobile |
Subscribe |
Tools |
Help |
ACP Online
|
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
1 August 1997 | Volume 127 Issue 3 | Pages 177-185
Background: Recommended therapeutic international normalized ratios (INRs) for oral anticoagulation in patients with lupus anticoagulants who sustain a thromboembolic event are controversial. Patients with lupus anticoagulants often have a prolonged prothrombin time, which may complicate management of anticoagulant therapy.
Objectives: To determine the validity of the INR as a monitor for warfarin therapy in patients with lupus anticoagulants and to investigate alternate approaches to monitoring warfarin therapy in these patients.
Design: Prospective case series.
Setting: Tertiary care hospital.
Patients: 34 patients with lupus anticoagulants.
Measurements: Prothrombin times were determined by using several thromboplastins, and INRs were calculated for the patients receiving warfarin. Factor II levels, chromogenic factor X levels, and prothrombin-proconvertin times were determined for patients receiving warfarin.
Results: For patients with lupus anticoagulants who were not receiving warfarin, prothrombin times were often elevated and varied significantly with different thromboplastins. Individual thromboplastins differed in sensitivity to the presence of a lupus anticoagulant. For patients receiving warfarin, INRs obtained by using different thromboplastins greatly varied and often overestimated the extent of anticoagulation. Chromogenic factor X levels and prothrombin-proconvertin times correlated well with each other and with established therapeutic ranges.
Conclusions: Lupus anticoagulants can influence prothrombin times and lead to INRs that do not accurately reflect the true level of anticoagulation. Use of the INR to standardize prothrombin times is invalid for some patients with lupus anticoagulants. To prevent supratherapeutic or subtherapeutic anticoagulation, these patients must be individually monitored with a test that is insensitive to lupus anticoagulants.
Author and Article Information
For author affiliations and current author addresses, see end of text.
ARTICLE
Monitoring Warfarin Therapy in Patients with Lupus Anticoagulants
For definitions of terms used in the article, see the glossary at end of text.
Acknowledgments: The authors thank the staff of the Duke Clinical Coagulation Laboratory for technical assistance; Gerold Bepler, MD, Stephen Kantrow, MD, and Charles Greenberg, MD, for critical review of the manuscript; and Victor Hasselblad, PhD, for statistical analysis.
Grant Support: In part by an Institutional Research Grant (ACS-IRG 158K) from the American Cancer Society; a Clinician-Scientist Award Initiation Grant (91-149) from the American Heart Association and Genentech, Inc.; and a grant (MO1-RR-30) from the National Center for Research Resources, General Clinical Research Centers Program, National Institutes of Health. Dr. Ortel is a Pew Scholar in the Biomedical Sciences.
Requests for Reprints: Thomas L. Ortel, MD, PhD, Box 3422, Department of Medicine, Division of Hematology, Duke University Medical Center, Durham, NC 27710.
Current Author Addresses: Dr. Moll: Franz-Volhard-Klinik, Virchowklinikum, Medizinische Fakultat Charite der Humboldt-Universitt zu Berlin, 13122 Berlin, Germany.
This article has been cited by other articles:
|
|
 |
|
  J. Ansell, J. Hirsh, E. Hylek, A. Jacobson, M. Crowther, and G. Palareti Pharmacology and Management of the Vitamin K Antagonists: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition) Chest, June 1, 2008; 133(6_suppl): 160S - 198S. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 K. L. Scolaro, P. L. Stamm, and K. B. Lloyd Devices for ambulatory and home monitoring of blood pressure, lipids, coagulation, and weight management, part 2 Am. J. Health Syst. Pharm., September 15, 2005; 62(18): 1894 - 1903. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 T. L. Ortel Thrombosis and the Antiphospholipid Syndrome Hematology, January 1, 2005; 2005(1): 462 - 468. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. K. Wittkowsky Anticoagulation in Hypercoagulable Conditions: Special Considerations in the Treatment and Prevention of Venous Thromboembolism Journal of Pharmacy Practice, October 1, 2004; 17(5): 308 - 316. [Abstract] [PDF]
|
|
|
|
|
|
J. Ansell, J. Hirsh, L. Poller, H. Bussey, A. Jacobson, and E. Hylek The Pharmacology and Management of the Vitamin K Antagonists: The Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy Chest, September 1, 2004; 126(3_suppl): 204S - 233S. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. A. Ozturk, I. C. Haznedaroglu, M. Turgut, and H. Goker Current Debates in Antiphospholipid Syndrome: The Acquired Antibody-Mediated Thrombophilia Clinical and Applied Thrombosis/Hemostasis, April 1, 2004; 10(2): 89 - 126. [Abstract] [PDF]
|
|
|
|
 |
|
 A. S Trask, R. C Gosselin, J. A Diaz, and W. E Dager Warfarin Initiation and Monitoring with Clotting Factors II, VII, and X Ann. Pharmacother., February 1, 2004; 38(2): 251 - 256. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. Hirsh, V. Fuster, J. Ansell, and J. L. Halperin American Heart Association/American College of Cardiology Foundation guide to warfarin therapy J. Am. Coll. Cardiol., May 7, 2003; 41(9): 1633 - 1652. [Full Text] [PDF]
|
|
|
|
 |
|
 J. Hirsh, V. Fuster, J. Ansell, and J. L. Halperin American Heart Association/American College of Cardiology Foundation Guide to Warfarin Therapy Circulation, April 1, 2003; 107(12): 1692 - 1711. [Full Text] [PDF]
|
|
|
|
 |
|
 S. R Deitcher and M. P. Gomes Hypercoagulable state testing and malignancy screening following venous thromboembolic events Vascular Medicine, February 1, 2003; 8(1): 33 - 46. [Abstract] [PDF]
|
|
|
|
 |
|
 T. G. DeLoughery Thrombocytopenia in Critical Care Patients J Intensive Care Med, November 1, 2002; 17(6): 267 - 282. [Abstract] [PDF]
|
|
|
|
 |
|
 B. Goichot, A.-E. Perrin, and R. H. Thomas Hypercoagulable Disorders Arch Intern Med, August 12, 2002; 162(15): 1785 - 1787. [Full Text] [PDF]
|
|
|
|
|
|
S. Moll and T. L. Ortel Antiphospholipid Antibodies Arch Intern Med, August 12, 2002; 162(15): 1783 - 1784. [Full Text] [PDF]
|
|
|
|
 |
|
 J. S. Levine, D. W. Branch, and J. Rauch The Antiphospholipid Syndrome N. Engl. J. Med., March 7, 2002; 346(10): 752 - 763. [Full Text] [PDF]
|
|
|
|
|
|
R. H. Thomas Hypercoagulability Syndromes Arch Intern Med, November 12, 2001; 161(20): 2433 - 2439. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. A. Ginsberg, M. A. Crowther, R. H. White, and T. L. Ortel Anticoagulation Therapy Hematology, January 1, 2001; 2001(1): 339 - 357. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. Hirsh, J. E. Dalen, D. R. Anderson, L. Poller, H. Bussey, J. Ansell, and D. Deykin Oral Anticoagulants: Mechanism of Action, Clinical Effectiveness, and Optimal Therapeutic Range Chest, January 1, 2001; 119(1_suppl): 8S - 21S. [Full Text] [PDF]
|
|
|
|
|
|
J. Ansell, J. Hirsh, J. Dalen, H. Bussey, D. Anderson, L. Poller, A. Jacobson, D. Deykin, and D. Matchar Managing Oral Anticoagulant Therapy Chest, January 1, 2001; 119(1_suppl): 22S - 38S. [Full Text] [PDF]
|
|
|
|
|
|
T. M. Hyers, G. Agnelli, R. D. Hull, T. A. Morris, M. Samama, V. Tapson, and J. G. Weg Antithrombotic Therapy for Venous Thromboembolic Disease Chest, January 1, 2001; 119(1_suppl): 176S - 193S. [Full Text] [PDF]
|
|
|
|
 |
|
 V. Pengo, T. Brocco, A. Biasiolo, P. Rampazzo, P. Carraro, and R. Zamarchi Procoagulant Effect of Anti-beta 2-Glycoprotein I Antibodies With Lupus Anticoagulant Activity Blood, December 1, 1999; 94(11): 3814 - 3819. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. Bucciarelli, A. Alatri, M. Moia, M. A. Khamashta, F. M.K. Williams, B. J. Hunt, C. Kearon, J. S. Ginsberg, and M. Gent Anticoagulation for Venous Thromboembolism N. Engl. J. Med., August 12, 1999; 341(7): 539 - 540. [Full Text]
|
|
|
|
 |
|
 E. Cretel, P. Cacoub, D. L. Thi Huong, A. Gompel, Z. Amoura, and J.-C. Piette Massive ovarian haemorrhage complicating oral anticoagulation in the Antiphospholipid Syndrome: a report of three cases Lupus, July 1, 1999; 8(6): 482 - 485. [Abstract] [PDF]
|
|
|
|
|
|
M. Galli and T. Barbui Antiprothrombin Antibodies: Detection and Clinical Significance in the Antiphospholipid Syndrome Blood, April 1, 1999; 93(7): 2149 - 2157. [Full Text] [PDF]
|
|
|
|
 |
|
 A. Sabet, W. L. Sibbitt Jr, C. A. Stidley, J. Danska, and W. M. Brooks Neurometabolite Markers of Cerebral Injury in the Antiphospholipid Antibody Syndrome of Systemic Lupus Erythematosus Stroke, November 1, 1998; 29(11): 2254 - 2260. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Z. Goldhaber Pulmonary Embolism N. Engl. J. Med., July 9, 1998; 339(2): 93 - 104. [Full Text] [PDF]
|
|
|
|
|
|
R. L. Bick and H. Kaplan Syndromes of Thrombosis and Hypercoagulability: Congenital and Acquired Thrombophilias Clinical and Applied Thrombosis/Hemostasis, January 1, 1998; 4(1): 25 - 50. [Abstract] [PDF]
|
|
Article
